Solventum Co. (NYSE:SOLV) Shares Sold by Twinbeech Capital LP

Twinbeech Capital LP lowered its stake in Solventum Co. (NYSE:SOLV) by 69.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 61,761 shares of the company’s stock after selling 140,750 shares during the quarter. Twinbeech Capital LP’s holdings in Solventum were worth $4,080,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Merit Financial Group LLC purchased a new position in shares of Solventum in the fourth quarter valued at approximately $235,000. Nisa Investment Advisors LLC boosted its stake in shares of Solventum by 2.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 33,546 shares of the company’s stock valued at $2,216,000 after purchasing an additional 708 shares during the period. Global Trust Asset Management LLC boosted its stake in shares of Solventum by 137.5% in the fourth quarter. Global Trust Asset Management LLC now owns 570 shares of the company’s stock valued at $38,000 after purchasing an additional 330 shares during the period. IVC Wealth Advisors LLC boosted its stake in shares of Solventum by 8.9% in the fourth quarter. IVC Wealth Advisors LLC now owns 7,243 shares of the company’s stock valued at $478,000 after purchasing an additional 594 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Solventum by 1,593.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,650 shares of the company’s stock valued at $968,000 after purchasing an additional 13,785 shares during the period.

Solventum Stock Down 1.5%

Shares of Solventum stock opened at $74.67 on Wednesday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The company has a 50 day moving average of $69.87 and a 200 day moving average of $71.31. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $12.92 billion and a P/E ratio of 34.57.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.15. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.02 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. As a group, research analysts forecast that Solventum Co. will post 6.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SOLV has been the subject of several recent research reports. Wells Fargo & Company raised their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Bank of America raised their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Morgan Stanley raised their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Piper Sandler upgraded shares of Solventum from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $87.00 in a research note on Monday. Finally, Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $80.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.